FDA Approves Mylan and Biocon’s Fulphila (pegfilgrastim-jmdb), the First Biosimilar to Neulasta Read more
Merck’s KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy Read more
Third Novartis Phase III trial shows Kisqali combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer Read more
EC approves Roche’s Perjeta for post-surgery treatment of HER2-positive early breast cancer at high risk of recurrence Read more
Alcami to Become Industry Leading Platform CDMO Following Acquisition by Madison Dearborn Partners Read more